A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-28Actual
Enrollment · participants87Actual
Source updated2025-09-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.